BioSpace News Archive

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Michael Inbar, CPA, MBA, has joined the Company as Senior Vice President, Finance, effective August 16, 2021.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today announced it will sponsor a satellite symposium at PAINWeek 2021 on Thursday, September 9 from 3:40 p.m. to 4:30 p.m. Eastern Time (12:40 p.m. to 1:30 p.m. Pacific Time) in Castellana 1 Ballroom, The Cosmopolitan of Las Vegas

PharmAbcine Inc. today announced it submitted a Patent Cooperation Treaty (PCT), an international patent application, for an anti-ANG2 (Angiopoietin 2) antibody.

NanoView Biosciences today announced the appointment of Prof. Jan Lötvall, M.D., Ph.D., and Mark Plavsic , DVM, Ph.D., to its Scientific Advisory Board.

PaxMedica, Inc. today announced that it has been selected to present the results from its Phase 2 dose-ranging clinical trial evaluating PAX-101

AmerisourceBergen, a global healthcare company, bolstered its suite of manufacturer solutions through the addition of FirstView Financial.

Xeris Pharmaceuticals, Inc. today announced that it has recently been granted three new patents relating to its formulation technology platforms.

BioAge Labs, Inc. today announced the appointment of Rekha Hemrajani and Jason Coloma to the company’s board of directors.

Hancock Jaffe Laboratories, Inc. announced that promising two-year post-VenoValve® implantation data is being presented today at the Society for Vascular Surgery® (SVS) Annual Meeting in San Diego, CA by Dr. Jorge Ulloa, who was the Principal Investigator for the Company’s first-in-human VenoValve trial.

Coeptis Therapeutics, Inc. today announced it has exercised its option to acquire ownership in two technology assets that target CD38 cancers from VyGen-Bio, Inc., a majority-owned subsidiary of Vycellix, Inc.